2-Aminopropanediamide CAS 62009-47-6

Description:

Nomen chemicum: 2-Aminopropanediamide

CAS: 62009-47-6

Aspectus: Lumen Yellow Pulvis

Puritas: ≥98.0% (LCMS-ELSD)

Medium Favipiravir (CAS: 259793-96-9) in curatione aegrorum COVID-19 commendatarum a WHO

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer cum High puritate et stabulo Quality
Commercial Supple Favipiravir et intermedia:
Favipiravir CAS 259793-96-9
2-Aminopropanediamide CAS 62009-47-6
Diethyl Aminomalonatum Hydrochloridum CAS 13433-00-6
3,6-Dichloropyrazinum-2-Carbonitrile CAS 356783-16-9
3,6-Difluoropyrazine-2-Carbonitrile CAS 356783-28-3
6-Fluoro-3-Hydroxypyrazine-2-Carbonitrile CAS 356783-31-8
6-Bromo-3-Hydroxypyrazine-2-Carboxamide CAS, 259793-88-9
3-Hydroxypyrazine-2-Carboxamide CAS 55321-99-8

Chemical Properties:

Nomen chemicum	2-Aminopropanediamide
Synonyma	Aminomalonamide
CAS Number	62009-47-6
CATTUS Number	RF-PI224
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C3H7N3O2
M. Pondus	117.11
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Lumen Yellow Pulvis
Infrared Imaginis	Conformat ut Structure
Puritas	≥98.0% (LCMS-ELSD)
Liquescens punctum	180.0~185.0℃
Damnum in Siccatio	≤0.50%
Residere in Ignition	≤0.50%
Test Standard	Enterprise Standard
Consuetudinem	Pharmaceutical Intermedia;Favipiravir (CAS: 259793-96-9)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.

commoda:

FAQ:

Applicatio:

Shanghai Ruifu Chemical Co., Ltd. est primarius fabricae et supplementi 2-Aminopropanediamidei (CAS: 62009-47-6) cum qualitate, late in synthesi organica, synthesi pharmaceuticae intermediorum et pharmaceuticae Ingredientis (API) synthesis activae.

2-Aminopropanediamide (CAS: 62009-47-6) medium est Favipiravir (CAS: 259793-96-9) in curatione aegrorum cum COVID-19 commendata a WHO

2-Aminopropanediamide (CAS: 62009-47-6) synthesis derivatorum Imidazole usurpatur.